Phase Forward to Lead Sessions at CDISC Interchange Japan 2010
July 19 2010 - 7:00PM
Business Wire
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, will
participate at CDISC Interchange Japan 2010, July 20-23 at the
Toshi Center Hotel in Tokyo.
At CDISC Interchange Japan, company representatives will lead
four sessions on key industry data standards and drug safety
related issues:
Who: Robbert P. van Manen,
Senior Technical Solutions Consultant, Phase Forward
What: “Define.XML - It’s
Not Just for Submissions Any More”
When: Tuesday, July 20,
3:30 – 5:00 p.m. JST (Japan Standard Time)
Who: Robbert P. van Manen,
Senior Technical Solutions Consultant, Phase Forward
What: “Doing More with SDTM
– Safety Signal Detection on Clinical Trial Data”
When: Wednesday, July 21,
9:00 – 10:45 a.m. JST
Who: Joerg Dillert,
Principal Consultant, Phase Forward
What: “E2B under the
Umbrella of HL7 and BRIDG: Looking To the Future of Data
Integrations between Pharmacovigilance (E2B) and Clinical Data
Management”
When: Wednesday, July 21,
9:00 – 10:45 a.m. JST
Who: Herve Ouambo,
Principal Technical Consultant, Phase Forward
What: “Simplifying Trial
Data Extraction with CDISC ODM as a Web Service Interface”
When: Wednesday, July 21,
3:45 – 4:45 p.m. JST
Phase Forward will also be exhibiting booth #7 at the CDISC
Interchange Japan 2010. Members of the media interested in speaking
with Phase Forward should contact Maria Sumner at +44 1628 640743
or maria.sumner@phaseforward.com or Juli Greenwood at 781-672-3137
or jgreenwood@chenpr.com.
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward’s products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Oct 2024 to Nov 2024
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Nov 2023 to Nov 2024
